Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFW NASDAQ:BLCM NASDAQ:NMTR NASDAQ:SXTPW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.01+6.1%$0.01$0.00▼$0.04N/AN/A135,541 shs250,437 shsBLCMBellicum Pharmaceuticals$0.07$0.08$0.06▼$1.31$727K1.3922,874 shs6,059 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs492 shsSXTPW60 Degrees Pharmaceuticals$0.04-40.6%$0.05$0.01▼$0.10N/AN/A14,877 shs17,342 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences+6.14%0.00%+47.56%+53.16%+19.81%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%SXTPW60 Degrees Pharmaceuticals0.00%-20.67%-37.41%-38.07%-13.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/ABLCMBellicum Pharmaceuticals 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ABLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33NMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ASXTPW60 Degrees Pharmaceuticals$665.45KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ABLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ANMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ASXTPW60 Degrees PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNFW180 Life SciencesN/AN/AN/ABLCMBellicum PharmaceuticalsN/A3.043.04NMTR9 Meters BiopharmaN/A0.590.59SXTPW60 Degrees PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/ABLCMBellicum Pharmaceuticals4.93%NMTR9 Meters Biopharma22.34%SXTPW60 Degrees PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/ABLCMBellicum Pharmaceuticals10.30%NMTR9 Meters Biopharma2.40%SXTPW60 Degrees PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableBLCM, NMTR, ATNFW, and SXTPW HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Inc (SXTP) - Investing.com UKJuly 23, 2025 | uk.investing.com60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella BacteriaJuly 19, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Secures $5M in Recent OfferingJuly 18, 2025 | tipranks.com60 Degrees Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and WarrantsJuly 15, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Inc (SXTP) - Investing.comJune 30, 2025 | investing.com60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJune 6, 2025 | usatoday.com60 Degrees Pharmaceuticals Introduces New 8-Count Bottle for ARAKODA® Malaria ProphylaxisJune 6, 2025 | nasdaq.com60 Degrees introduces eight-count bottle format for ARAKODAJune 4, 2025 | msn.com60 Degrees announces results from an insurance claims analysis on babesiosisJune 4, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Highlights Major Discrepancies in Babesiosis Diagnosis Estimates in U.S.April 24, 2025 | nasdaq.com60 Degrees Pharmaceuticals signs Patient License Agreement with YaleApril 8, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals Announces 2024 Annual ResultsMarch 28, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Inc trading halted, news pendingFebruary 21, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals files to sell 3.74M shares of common stock for holderFebruary 14, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals announces stock and warrant saleJanuary 29, 2025 | msn.comThe Market’s Eyeing 60 Degrees Pharmaceuticals (SXTP): Will the Surge Last?January 29, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLCM, NMTR, ATNFW, and SXTPW Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.01 +0.00 (+6.14%) As of 08/1/2025 02:41 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Bellicum Pharmaceuticals NASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.04 -0.02 (-40.57%) As of 07/31/2025 03:57 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
